Ultragenyx Pharmaceutical Inc. (RARE)
NASDAQ: RARE · Real-Time Price · USD
30.77
+1.52 (5.20%)
At close: Jun 26, 2026, 4:00 PM EDT
30.00
-0.77 (-2.50%)
After-hours: Jun 26, 2026, 6:54 PM EDT

Ultragenyx Pharmaceutical Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
3,0212,2223,8913,9363,2525,831
Market Cap Growth
-14.80%-42.91%-1.14%21.03%-44.23%-36.96%
Enterprise Value
3,6871,5853,3283,4022,5365,133
Last Close Price
30.7723.0042.0747.8246.3384.09
PS Ratio
4.513.306.959.078.9516.59
PB Ratio
--27.7715.2614.299.236.32
P/TBV Ratio
--115.3754.2921.897.63
EV/Sales Ratio
5.502.355.947.846.9814.61
Debt / Equity Ratio
--0.330.110.110.060.03
Net Debt / Equity Ratio
1.758.05-2.23-1.94-2.03-0.76
Net Debt / EBITDA Ratio
0.781.291.140.981.141.90
Net Debt / FCF Ratio
0.821.361.351.031.441.70
Asset Turnover
0.470.440.370.290.240.21
Inventory Turnover
2.062.251.951.481.321.09
Quick Ratio
1.642.182.132.323.024.24
Current Ratio
2.022.482.382.613.384.72
Return on Equity (ROE)
403.26%-608.47%-211.75%-193.34%-110.96%-43.72%
Return on Assets (ROA)
-39.92%-35.50%-35.93%-37.35%-42.65%-23.32%
Return on Invested Capital (ROIC)
-80.81%-75.93%-69.38%-76.87%-96.26%-62.88%
Return on Capital Employed (ROCE)
-52.96%-46.38%-45.24%-45.61%-49.44%-26.23%
Buyback Yield / Dilution
-6.60%-8.95%-23.13%-5.13%-3.13%-11.42%
Total Shareholder Return
-6.60%-8.95%-23.13%-5.13%-3.13%-11.42%
SEC Filings: 10-K · 10-Q